## 2-(4-Bromophenyl)thiazolidine: Structure and Importance in Research
**2-(4-Bromophenyl)thiazolidine** is an organic compound with the molecular formula C9H10BrNS. It's a thiazolidine derivative, characterized by a five-membered ring containing sulfur and nitrogen atoms. The presence of a 4-bromophenyl group attached to the 2-position on the thiazolidine ring defines its specific structure.
**Importance in Research:**
This compound is significant in research for several reasons:
* **Pharmacological Activity:** Thiazolidines, in general, have demonstrated potential pharmacological activity. 2-(4-Bromophenyl)thiazolidine itself, or its derivatives, might exhibit activity as:
* **Anti-inflammatory agents:** This could be due to the potential interaction with inflammatory pathways.
* **Anti-microbial agents:** The sulfur and nitrogen atoms in the thiazolidine ring can be modified to create compounds with antimicrobial properties.
* **Anti-cancer agents:** The specific structural features of this molecule might allow for interaction with targets related to cancer growth and development.
* **Chemical Synthesis:** This compound can serve as a building block or intermediate in the synthesis of other complex molecules with desired pharmacological properties. The presence of the bromine atom allows for further functionalization and modification through various reactions.
* **Biological Studies:** 2-(4-Bromophenyl)thiazolidine can be used as a probe to study the mechanisms of action of specific enzymes or receptors related to the biological activities mentioned above.
* **Material Science:** This compound might be used to create novel materials with specific properties. For example, the thiazolidine ring might be incorporated into polymers with unique characteristics.
**Current Research:**
Currently, there is ongoing research on 2-(4-Bromophenyl)thiazolidine and its derivatives to explore its potential applications in medicine, materials science, and other fields. Researchers are investigating its synthesis, modifications, and biological activity to uncover its full potential and potential benefits.
**Note:** It's important to note that while 2-(4-Bromophenyl)thiazolidine has promising properties, further research is needed to fully understand its potential applications and safety profile.
ID Source | ID |
---|---|
PubMed CID | 2771064 |
CHEMBL ID | 1536824 |
CHEBI ID | 105605 |
SCHEMBL ID | 2082827 |
Synonym |
---|
2-(4-bromophenyl)-1,3-thiazolidine |
MLS000678441 |
smr000323916 |
thiazolidine, 2-(4-bromophenyl)- |
2-(p-bromophenyl)thiazolidine |
brn 1211793 |
thiazolidine, 2-(p-bromophenyl)- |
CHEBI:105605 |
F1912-0001 |
2-(4-bromophenyl)thiazolidine |
AKOS003241051 |
NCGC00246619-01 |
HMS2721O10 |
2-(4-bromo-phenyl)-thiazolidine |
67086-81-1 |
AKOS016050467 |
2-(4-bromophenyl)-1,3-thiazolane |
SCHEMBL2082827 |
CHEMBL1536824 |
Q27183357 |
2-(4-bromo-phenyl)-thiazolidine, aldrichcpr |
CS-0268106 |
F0804-0839 |
mfcd00985113 |
A917827 |
DTXSID40902630 |
EN300-236021 |
Class | Description |
---|---|
organobromine compound | A compound containing at least one carbon-bromine bond. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 1.7783 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 35.4813 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
P53 | Homo sapiens (human) | Potency | 70.7946 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 89.1251 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 0.2512 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |